KR101823343B1 - A composition for enhancing anti-cancer effect of temozolomide comprising 20(s)-protopanaxatriol or salt thereof - Google Patents
A composition for enhancing anti-cancer effect of temozolomide comprising 20(s)-protopanaxatriol or salt thereof Download PDFInfo
- Publication number
- KR101823343B1 KR101823343B1 KR1020150156097A KR20150156097A KR101823343B1 KR 101823343 B1 KR101823343 B1 KR 101823343B1 KR 1020150156097 A KR1020150156097 A KR 1020150156097A KR 20150156097 A KR20150156097 A KR 20150156097A KR 101823343 B1 KR101823343 B1 KR 101823343B1
- Authority
- KR
- South Korea
- Prior art keywords
- temozolomide
- salt
- composition
- cancer
- anticancer activity
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J75/00—Processes for the preparation of steroids in general
Abstract
The present invention relates to a composition for promoting anticancer activity of temozolomide comprising 20 (S) -protopaxanol triol or a salt thereof as an active ingredient, a functional food containing the same and a composition containing 20 (S) (TMZ) in combination with 20 (S) -protopaxacatriol or a salt thereof, and more particularly to a pharmaceutical composition for treating cancer comprising as an active ingredient a triol or a salt thereof as an active ingredient. More particularly, the present invention relates to a composition comprising temozolomide Antitumor activity of temozolomide containing 20 (S) -proteinecaxtrirol or its salt as an active ingredient, which can effectively treat cancer using a synergistic anti-cancer effect occurring during treatment A functional food containing the same, and a pharmaceutical composition for treating cancer comprising as an active ingredient 20 (S) -protopicaxartriol or a salt thereof, .
Description
The present invention relates to a composition for promoting the anticancer activity of temozolomide comprising 20 (S) -proteinaceptriol or a salt thereof as an active ingredient, a health functional food for promoting anticancer activity of temozolomide containing the same and a temozolomide And 20 (S) -protopaxanol triol or a salt thereof as an active ingredient. More particularly, the present invention relates to a pharmaceutical composition for treating cancer comprising 20 (S) -protopaxanol triol or a salt thereof as an active ingredient, (S) -proteinaceptriol or a salt thereof, which can effectively treat cancer by using a synergistic anti-cancer effect which occurs when pancreatic triol or its salt is used in combination with the active ingredient , A composition for promoting anticancer activity of temozolomide, a health functional food for promoting anticancer activity of temozolomide comprising the same, and a composition containing 20 (S) -protonacosalmide It relates to pharmaceutical compositions for the treatment of a cancer, including all or a salt thereof as an active ingredient.
Panax ginseng C.A. Meyer (Panax ginseng, Korean ginseng) has been used in Asia for more than a thousand years and as a panacea. In the West, ginseng is also used as a supplement for improving health as a nourishing tonic which increases immune response such as enhancement of physical function and adaptation to physiological stress reaction. Ginseng is known as a functional food that promotes the synthesis of protein and nucleic acid, has liver function recovery and hyperactivity, increase exercise performance, anti-fatigue action, immunity enhancement, anti-cancer and antioxidant effect and promotes fat metabolism in the body.
The chemical composition of ginseng is mainly composed of 60% of carbohydrates, 10 ~ 11% of crude protein, 7 ~ 8% of crude fiber, 1 ~ 2% of crude fat, 3 ~ 4% of ash, and crude saponin content of 4 ~ 5% . Among them, saponin, which is known as a pharmacologically active ingredient with antidiabetic, anti-stress, antioxidant, anticancer, anti-inflammatory, immunity enhancement and central nervous system stability, was separated from glyoxamide The study began with the name "panaquilon", and since then research has been conducted in earnest from the late 1960s, and about 30 kinds of saponin structures are now known.
The chemical structure of saponin is composed of sugar glycoside and non sugar aglycoside. It is composed of triterpenoid saponin and steroid saponin depending on the skeletal structure of the non-sugar portion. . Saponin of ginseng is almost a triterpenoid saponin of dammarane type. It is a unique saponin that exists only in the plant of the panax, and it has the pharmacological effect that ginseng is different from other saponin containing plants. So far, dozens of ginseng saponins have been identified, and they are called ginsenoside, a glycoside contained in ginseng.
The ginsenosides were classified as Protopanaxadiols (PDs; Rb1, Rb2, Rc, Rd, Rg3, Rh2) and protopanaxtriols (PTs; Rg1, Rg2, Re, Rf, Rh1) Aglycone protopanaxatriol is produced by hydrolysis of the glucose moiety in the ginsenoside Rg1, ginsenoside Rg2, ginsenoside Re and ginsenoside Rf, which are proto-oncotic triol saponins.
Temozolomide (TMZ), a type of chemotherapeutic drug, is a chemotherapeutic agent approved for the treatment of brain tumors (marketed by Schering Corp. under the Temodal (R) brand name in the United States, Temodal (R)). The chemical name of temozolomide is 3,4-dihydro-3-methyl-4-oximoimidazo [5,1-d] -as- tetrazine- 8-carboxamide (see U.S. Patent No. 5,260,291) Cytotoxicity is thought to be due to DNA alkylation of temozolomide and the metabolite MTIC (3-methyl- (triazen-1-yl) imidazole-4-carboxamide).
On the other hand, the highly malignant glioma glioma includes reverse glioma and polymorphic glioblastoma, accounting for approximately 60% of primary malignant brain tumors. The survival period is 9 to 16 months and the prognosis is poor.
The most common prognostic factors are age at the time of diagnosis, age at the time of diagnosis, histologic subtype, systemic status, surgical resection, neurological function, and radiation dose. There is a bar. McGirt et al reported that the prognosis was poorer in patients with less surgical resection compared with those who underwent complete resection (McGirt MJ, Chaichana KL, Gathinji M, et al. Independent association of extent of resection with survival in patients with malignant brain astrocytoma J Neurosurg 2009; 110: 156-162).
Therefore, maximum surgical resection is necessary and the role of adjuvant therapy may be increased if residual tumor is present. Based on the results of this study, simultaneous treatment with temozolomide and radiation was established as a standard treatment.
Therefore, it is required to develop a treatment method that can improve the effectiveness of the current standard treatment so that an effective auxiliary treatment can be performed after the operation.
Thus, the present inventors have found that a synergistic anti-cancer effect occurs when temozolomide (TMZ) used in standard therapy is used in combination with 20 (S) -protopaxacatriol or a salt thereof The present inventors have found that effective chemotherapy is possible and completed the present invention.
It is an object of the present invention to provide a composition for promoting anticancer activity of temozolomide comprising 20 (S) -proteinaxantriol or a salt thereof as an active ingredient.
Still another object of the present invention is to provide a functional food for promoting anticancer activity of temozolomide comprising the composition for promoting anticancer activity.
Another object of the present invention is to provide a pharmaceutical composition for treating cancer comprising 20 (S) -proprofenacatriol or a salt thereof and temozolomide as an active ingredient.
In order to solve the above-mentioned problems, the present invention provides a composition for promoting anticancer activity of temozolomide comprising 20 (S) -proteinaxanthriol or a salt thereof as an active ingredient, having the following general formula (I).
(I)
According to a preferred embodiment of the present invention, the composition for enhancing anticancer activity may be co-administered with cancer patients together with temozolomide.
According to another preferred embodiment of the present invention, the 20 (S) -protopaxacatriol and temozolomide can be administered at a molarity ratio of 1: 3.34 to 1: 5000.
According to another preferred embodiment of the present invention, the cancer patient to which the anticancer activity promoting composition and the temozolomide are administered in combination is selected from the group consisting of metastatic melanoma, malignant melanoma, malignant glioma, glioblastoma, lung cancer, breast cancer, Colon cancer, rectal cancer, carcinoma, sarcoma, lymphoma, leukemia, adventitial adenocarcinoma, and bacterial sarcoma.
The present invention also provides a functional food for promoting anticancer activity of temozolomide comprising the various types of compositions for promoting anticancer activity as described above.
The present invention also provides a pharmaceutical composition for treating cancer comprising 20 (S) -protopaxacatriol or a salt thereof and a temozolomide as an active ingredient, having the formula (I):
(I)
According to a preferred embodiment of the present invention, the pharmaceutical composition may comprise 20 (S) -protopaxacatriol and temozolomide in a molarity ratio of 1: 3.34 to 1: 5000.
According to another preferred embodiment of the present invention, the cancer that can be treated with the pharmaceutical composition of the present invention is a metastatic melanoma, malignant melanoma, malignant glioma, glioblastoma, lung cancer, breast cancer, testicular cancer, colon cancer, rectal cancer, , Sarcoma, lymphoma, leukemia, adventitial adenocarcinoma, and bacterial sarcoma.
The composition for enhancing anticancer activity of temozolomide comprising 20 (S) -protopaxanol triol or a salt thereof as an active ingredient of the present invention, when administered to a cancer patient in combination with temozolomide, The efficacy of standard therapy can be improved by applying chemotherapy to temporomandibular joints with temozolomide, which has been established as a standard treatment after surgery for high-grade malignant glioma. .
Furthermore, the functional food for enhancing anticancer activity of temozolomide including the composition for enhancing anticancer activity may be administered to cancer patients treated with temozolomide to enhance the anticancer activity of temozolomide.
The pharmaceutical composition comprising 20 (S) -profloxacatriol or a salt thereof and temozolomide as an active ingredient also provides the anticancer activity of the enhanced temozolomide, so that it is more effective than the administration of temozolomide alone Therapeutic efficacy can be enhanced and can be applied to standard therapy to enhance the effectiveness of standard therapy.
BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a graph showing the anticancer effect of the in vitro C6 rat glioblastoma cell line treated with 10 .mu.M, 20 .mu.M or 30 .mu.M of 20 (S) -protopanaxatriol in combination with the control group.
FIG. 2 shows cytomorphological observations of the combined treatment effect of TMZ with 20 (S) -proteinaceptidriol in an in vitro C6 rat glioblastoma cell line.
Hereinafter, the present invention will be described in more detail.
As described above, the role of adjuvant therapy in the presence of residual tumor after a high malignant glioma glioma surgery may become even larger. Based on the results of this study, simultaneous treatment with temozolomide and radiation is the standard treatment . Therefore, there is a need to develop a treatment method that can enhance the effectiveness of current standard therapy so that more effective adjuvant therapy can be performed after surgery.
Accordingly, the present invention has been made to solve the above-mentioned problems by providing a composition for promoting anticancer activity of temozolomide comprising 20 (S) -protopaxanol triol or a salt thereof as an active ingredient. The composition for enhancing anticancer activity of the present invention can be effectively used for chemotherapy by increasing the anticancer effect compared with the single dose of temozolomide when used in combination with temozolomide and is also a standard treatment after high malignant glioblastoma surgery It can be applied to concurrent therapy with established temozolomide and radiation to improve the effectiveness of standard therapy.
In addition, 20 (S) - protopanaxatriol or its salt in combination with temozolomide in a low concentration range that does not affect cancer cell survival when administered alone has a synergistic anticancer effect, (S) -proproximatriol or its salt alone can enhance the anti-cancer effect of temozolomide.
The terms used in the present invention are defined as follows.
The term " salt " includes both acid and base addition salts. Exemplary salts include but are not limited to sulfate, citrate, acetate, oxalate, chloride, bromide, iodide, nitrate, bisulfate, phosphate, acid phosphate, isonicotinate, lactate, salicylate, But are not limited to, lactose, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucuronate, (I.e., 1,1'-methylene-vice- (2-hydroxy-3-naphthoate)) salt may be reacted with a compound of formula But is not limited to these. Salts may include the inclusion of other molecules, such as acetate ions, succinate ions, or other counterions. The counterion may be any organic or inorganic moiety that stabilizes the charge in the parent compound.
The term " patient " means any single entity that requires treatment, including a human, cow, dog, guinea pig, rabbit, chicken, insect, In addition, any subject who participates in a clinical study test that does not show any disease clinical findings, or who participates in epidemiological studies or used as a control group is included.
The term " pharmaceutical composition " refers to a mixture of 20 (S) -protopaxacatriol or a salt thereof of the present invention and other chemical components such as a diluent or carrier in temozolomide.
The term " carrier " is defined as a compound that facilitates the addition of a compound into a cell or tissue. For example, dimethylsulfoxide (DMSO) is a commonly used carrier that facilitates the introduction of many organic compounds into cells or tissues of an organism.
The term " diluent " is defined as a compound that not only stabilizes the biologically active form of the compound of interest, but also dilutes in water to which the compound is dissolved. Salts dissolved in buffer solutions are used as diluents in the art. A commonly used buffer solution is phosphate buffered saline, since it mimics the salt state of the human solution. Since buffer salts can control the pH of the solution at low concentrations, buffer diluents rarely modify the biological activity of the compounds.
The term " cancer " " tumor " or " malignancy " refers to or describes the physiological condition of a mammal generally characterized by unregulated cell growth.
The term " about " refers to a reference quantity, level, value, number, frequency, percentage, dimension, size, quantity, weight or length of 30, 25, 20, 25, 10, 9, 8, 7, , Level, value, number, frequency, percent, dimension, size, quantity, weight, or length that varies from one to three, two, or one percent.
The term " synergistic " refers to the effect that occurs when each component is administered in combination (combination) is greater than the sum of the effects that occur when it is administered alone as a single component [Chou and Talalay, Adv. Enzyme. Regul., 22: 27-55, 1984). The composition for enhancing anticancer activity of temozolomide comprising 20 (S) -protopaxanol triol or its salt as an active ingredient of the present invention acts to increase the cancer treatment effect by coadministering with temozolomide, Of the 20 (S) -protopaxanol triol or its salt and the composition comprising temozolomide as an active ingredient also have the same function.
The term " administered in combination " means that a compound or ingredient is administered to a patient together. The administration of each compound or component together means that each component can be administered sequentially at the same time or in any order or at different times to achieve the desired therapeutic effect.
The term " treatment " means an approach to obtaining beneficial or desired clinical results. For purposes of the present invention, beneficial or desired clinical results include, but are not limited to, alleviation of symptoms, reduction in the extent of disease, stabilization (i.e., not worsening) of the disease state, (Either partially or totally), detectable or undetected, whether or not an improvement or temporary relief or reduction Also, " treatment " may mean increasing the survival rate compared to the expected survival rate when not receiving treatment. &Quot; Treatment " refers to both therapeutic treatment and prophylactic or preventative measures. Such treatments include treatments required for disorders that have already occurred as well as disorders to be prevented. &Quot; Palliating " a disease may reduce the extent of disease states and / or undesirable clinical manifestations and / or slow the time course of progression, It means to lose.
All technical terms used in the present invention are used in the sense that they are generally understood by those of ordinary skill in the relevant field of the present invention unless otherwise defined. Also, preferred methods or samples are described in this specification, but similar or equivalent ones are also included in the scope of the present invention.
The present invention provides a composition for promoting anticancer activity of temozolomide comprising 20 (S) -proteinaxanthriol or a salt thereof as an active ingredient having the following formula (I).
(I)
The 20 (S) -protonacucatriol is in the form of an aglycone, and the term " aglycone " is an abbreviation of a ginsenoside.
The composition for enhancing anticancer activity may be co-administered with cancer patients together with temozolomide. More specifically, the composition for enhancing anticancer activity of the present invention can be administered to cancer patients simultaneously with the temozolomide or sequentially in any order or at different times.
The cancer patient is not limited as long as the patient is a cancer patient who is treated with an anticancer drug of the present invention, but preferably the metastatic melanoma, malignant melanoma, malignant glioma, glioblastoma and other brain cancer, lung cancer, breast cancer, testicular cancer, colon cancer, rectal cancer , A cancer, a sarcoma, a lymphoma, a leukemia, a reverse cell tumor, and a bacterial sarcoma. More preferably, the cancer patient may be a patient suffering from malignant glioma or glioblastoma.
The 20 (S) -proteinaceptol triol and temozolomide of the composition for enhancing anticancer activity of the present invention have a weight ratio of 1: 3.34 to 1: 5000, preferably 1: 5 to 1: 500, more preferably 1:10 To 1: 100. ≪ / RTI >
The maximum concentration of 20 (S) -proto pilecoxatriol in the molar concentration ratio is administered below the concentration range that is toxic to normal cells.
If 20 (S) - protopanaxatriol is administered at a dose of less than 0.1 μM based on 500 μM of temozolomide, the anticancer activity of temozolomide can not be effectively increased. If temozolomide is administered at a dose of 500 μM If 20 (S) - protopanaxatriol is administered in excess of 150 μM, it may cause toxicity to normal cells that are not cancer cells.
As shown in Fig. 1, when the C6 rat glioblastoma cell line was treated alone with 500 [mu] M temozolomide, the cell viability was reduced by about 30% compared to the control (CON) When treated with protopanax triol alone, no difference was observed between the control and the untreated control, indicating that the cell viability was not affected. However, the combined treatment of 500 μM temozolomide with 30 μM 20 (S) -proprofenacatriol resulted in a 30% reduction in cell viability compared to 500 μM temozolomide alone, and a combination of 500 μM temozolomide and 20 μM When combined with 20 (S) -proproximate triol, cell viability was reduced by about 20% as compared to 500 μM temozolomide alone, compared with 500 μM temozolomide and 10 μM 20 (S) When triol was used in combination, cell viability was reduced by about 10% as compared with the case of treatment with 500 μM temozolomide alone. This suggests that even when the concentration of 20 (S) - protopanaxatriol alone does not affect the viability of the cells, the anticancer activity of temozolomide is enhanced when the combination with temozolomide is used, It can be effectively treated.
The present invention also provides a health functional food for promoting anticancer activity of temozolomide comprising the various anticancer activity enhancing compositions of the present invention described above.
The health functional food may contain flavoring agents such as various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, coloring agents and thickening agents (cheese, chocolate etc.), pectic acid and its salts, alginic acid and its salts, Organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated drinks, and the like. It can also contain natural fruit juices and pulp for the production of fruit juices and vegetable drinks. These components may be used independently or in combination. The health functional food may be in the form of any one of meat, sausage, bread, chocolate, candy, snack, confectionery, pizza, ramen, gum, ice cream, soup, beverage, tea, functional water, drink, alcohol and vitamin .
In addition, the health functional food may further include food additives, and the suitability of the food functional food as a " food additive " is not limited to the corresponding items in general rules and general test methods approved by the Food and Drug Administration Shall be determined according to the relevant standards and standards.
Examples of the products that have been used in the above-mentioned "food additives" include natural products such as ketones, chemical products such as glycine, potassium citrate, nicotinic acid and cinnamic acid, sensory coloring matter, licorice extract, crystalline cellulose, high- - Mixed preparations such as a sodium glutamate preparation, a noodle-added alkaline agent, a preservative preparation, a tar coloring agent and the like.
In this case, the composition for enhancing anticancer activity according to the present invention, which is added to foods in the course of manufacturing a health functional food, can appropriately increase or decrease the content of the anticancer activity enhancing composition according to need, The dose may be used in accordance with the effective dose of the pharmaceutical composition, and the amount of the active ingredient to be mixed may be appropriately determined depending on the purpose of use such as prevention or therapeutic treatment. In the case of long-term consumption intended for health and hygiene purposes or for health control purposes, it may be below the above range.
The present invention provides a pharmaceutical composition for treating cancer comprising 20 (S) -protopaxacatriol or a salt thereof and a temozolomide as an active ingredient, having the following formula (I).
(I)
The 20 (S) -protonacnaphthol triol is in the aglycone form.
The pharmaceutical compositions of the present invention may further comprise suitable carriers, excipients and diluents conventionally used in the manufacture of pharmaceutical compositions.
The pharmaceutical composition according to the present invention may be formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, oral preparations, suppositories and sterilized injection solutions according to a conventional method .
Examples of carriers, excipients and diluents that may be contained in the composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin , Calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
In the case of formulation, a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, or a surfactant is usually used.
Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient such as starch, calcium carbonate, sucrose or lactose , Gelatin, and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Examples of the liquid preparation for oral administration include suspensions, solutions, emulsions, and syrups. In addition to water and liquid paraffin, simple diluents commonly used, various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included .
Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Examples of the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. Examples of suppository bases include witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin, and the like.
The amount of the composition of the present invention to be used may vary depending on the age, sex, and body weight of the patient, and may vary depending on the state of the subject to be treated, the specific category or type of cancer to be treated, Lt; RTI ID = 0.0 >
The pharmaceutical composition may be administered to mammals such as rats, mice, livestock, humans, and the like in a variety of routes. All modes of administration may be expected, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intra-uterine dural or intracerebral injection.
In particular, it can be administered by any medically appropriate method, for example by injection into normal cerebrospinal fluid, such as normal intravenous or intraarterial administration. In some cases, intradermal administration, intracavity administration, intrathecal administration, tumor or direct administration to the arteries supplying the tumor is advantageous. When the tumor or a portion thereof has previously been removed by surgical operation, the therapeutic agent can be delivered directly to the tumor site (and, in particular, the enclosed cavity or "ablation "Quot; resection cavity ").
The composition of the present invention is appropriately selected depending on the degree of absorption of the active ingredient in the body, the excretion rate, the age and weight of the patient, the sex and condition of the patient, the severity of the disease to be treated and the like, but is generally 0.01 to 250 mg / 0.1 mg / kg to 100 mg / kg. The unit dosage formulations thus formulated may be administered several times at predetermined time intervals as necessary.
The pharmaceutical composition of the present invention is prepared by mixing 20 (S) -proteinaxantriol and temozolomide in a ratio of 1: 3.34 to 1: 5000, preferably 1: 5 to 1: 500, more preferably 1: : 100. ≪ / RTI >
The maximum concentration of 20 (S) -proteinaceptidriol in the molar concentration ratio is included in the pharmaceutical composition at a concentration range below toxic to normal cells.
As shown in Figure 1, the molarity ratio of 20 (S) -proto ponexatriol and temozolomide to 1:50 (10 [mu] M 20 (S) -proprofenacatriol and 500 [mu] M temozolomide) (20 [mu] M of 20 (S) -proprofenacatriol and 500 [mu] M of temozolomide) at a molar concentration ratio of 1:25 (20 [ Of the present invention, the anticancer activity of temozolomide is remarkably increased as compared with the administration of temozolomide alone. Therefore, the pharmaceutical composition of the present invention can treat cancer more effectively than conventional temozolomide.
The cancer that can be treated with the pharmaceutical composition of the present invention is not limited as long as it is a cancer disease in which temozolomide is used as an anticancer agent, but it is preferably a cancer selected from metastatic melanoma, malignant melanoma, malignant glioma, glioblastoma, lung cancer, Testicular cancer, colon cancer, rectal cancer, carcinoma, sarcoma, lymphoma, leukemia, adventitial adenocarcinoma, and bacterial sarcoma. More preferably, the cancer may be malignant glioma or glioblastoma.
The present invention will now be described more specifically with reference to the following examples. However, the following examples should not be construed as limiting the scope of the present invention, but should be construed to facilitate understanding of the present invention.
<Preparation Example 1>
Cell cultures and 20 (S) -proteinaceptanol Of temozolomide Ready
C6 rat glioblastoma cell line (KCLB No. 10107) was obtained from Korean Cell Line Bank. The cells were inoculated into a humidified environment of 5% CO 2 in Dulbecco's Eagle's medium (DMEM, high glucose) supplemented with 10% fetal bovine serum (FBS), 100 units / mL penicillin and 100 μg / mL streptomycin, Lt; / RTI >
The ginsenoside standard 20 (S) -protopanaxatriol used in the examples was obtained from Ambo Institute (Seoul, Korea) and temozolomide was obtained from Sigma (Product # T2577).
20 (S) - protopanaxatriol Temozolomide Observation of cells according to the effect of enhancing anticancer activity
Cells cultured in Preparation Example 1 were either treated with (CON), 0.53% dimethylsulfoxide (DMSO) for 96 hours, or with 500 μM temozolomide and 30 μM 20 (S) (S) -protopaxacetriol, 500 μM temozolomide, 20 μM 20 (S) -protopaxacatriol and 500 μM temozolomide, and 10 μM 20 (S ) - protopanaxatriol in combination with temozolomide and 20 (S) - protopanaxatriol in combination.
The C6 cells were then observed through a microscope (Model: Axio Observer Z1, Calcina, Germany) and the results are shown in FIG.
(CON), cells treated with 0.53% dimethylsulfoxide (DMSO) for 96 hours (Solvent control, SC) and cells treated with 30 μM 20 (S) -proteinaceptanol As shown in the microscope image of FIG. 1, it was observed that the surviving C6 cells (elongated form) were closely arranged, and it was confirmed that the survival rate of C6 cells was not changed.
However, when 500 μM temozolomide alone was administered, a large number of dead C6 cells (rounded form) were observed, and 500 μM temozolomide, 10 μM 20 (S) -proteinaxacatriol, 500 μM temozolomide and 20 μM 20 S) -protopaxanol triol, and 500 μM temozolomide and 30 μM 20 (S) -protopaxanol triol, respectively, the survival of C6 survived more than 500 μM temozolomide alone It was observed that the cells were significantly reduced. It was confirmed that the combination of temozolomide and 20 (S) - protopanaxatriol showed a synergistic anticancer effect in proportion to the concentration of 20 (S) - protopanaxatriol.
20 (S) - protopanaxatriol Temozolomide The effect of enhancing anticancer activity MTT black
(4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide (MTT) was used to evaluate the effect of 20 (S) The test was conducted. After using a cell culture in Preparation Example 1 was dispensed into each well of a 96 well plate for 53 cells in single cell suspension was incubated at 37 ℃ for 24 hours. Cells were then treated with 0.53% dimethylsulphoxide (DMSO) for 96 hours or with 500 μM temozolomide and 30 μM 20 (S) -protonacaxatriol for 96 hours, either alone (S) -protopaxacetriol and 500 μM temozolomide and 10 μM 20 (S) -protein, respectively, with 500 μM temozolomide and 30 μM 20 (S) -protopaxacetriol, 500 μM temozolomide and 20
C6 rat glioblastoma cell line treated with 500 μM temozolomide resulted in a 30% reduction in cell viability compared to the untreated control (CON) and only treatment with 30 μM 20 (S) -protraxecatriol In one case, no difference was observed between the control and the untreated control, indicating that the cell viability was not affected. However, the combined treatment of 500 μM temozolomide with 30 μM 20 (S) -proprofenacatriol resulted in a 30% reduction in cell viability compared to 500 μM temozolomide alone, and a combination of 500 μM temozolomide and 20 μM When 20 (S) -proproximate triol was coadministered, the cell viability was reduced by about 20% compared to 500 μM temozolomide alone, and the cell viability was reduced by about 20% compared to 500 μM temozolomide alone and with 20 μM 20 (S) When triol was used in combination, cell viability was reduced by about 10% as compared with the case of treatment with 500 μM temozolomide alone.
Surprisingly, even when the concentration of 20 (S) -protopaxanol triol alone does not affect cell viability, the combination of temozolomide can increase the anticancer activity of temozolomide, It can be seen from the second embodiment.
Formulation example
< Formulation example 1 > The composition for enhancing anticancer activity Powder Produce
20 (S) - protopanaxatriol was mixed with 100 mg of lactose and 10 mg of talc and filled in airtight bags to prepare powders.
< Formulation example 2 > Preparation of Tablets of Composition for Promoting Anticancer Activity
14.3 mg of 20 (S) -proprofenacatriol was mixed with 100 mg of corn starch, 100 mg of lactose and 2 mg of magnesium stearate, and tableted according to a conventional preparation method.
< Formulation example 3> Preparation of capsules of composition for enhancing anticancer activity
14.3 mg of 20 (S) - protopanaxatriol was mixed with 100 mg of corn starch, 100 mg of lactose and 2 mg of magnesium stearate according to a conventional capsule preparation method, and filled in a gelatin capsule to prepare a capsule.
< Formulation example 4> Preparation of Injection of Composition for Enhancing Anticancer Activity
(S) - protopanaxatriol (14.3 mg) per 1 ampoule (2 ml) according to the usual injection preparation method was prepared containing sterile distilled water suitable amount and pH adjuster proper amount.
< Formulation example 5> a composition for promoting anticancer activity Liquid Produce
(S) -protopanaxatriol (14.3 mg), 10 g of isomerized sugar and 5 g of mannitol were dissolved in an appropriate amount of purified water, and the mixture was mixed with an appropriate volume of lemon fragrance. Then, purified water was added thereto 100 ml, and then filled in a brown bottle and sterilized to prepare a liquid preparation.
< Formulation example 6> A pharmaceutical composition for treating cancer Powder Produce
20 (S) - protopanaxatriol was mixed with 97 mg of temozolomide, 100 mg of lactose and 10 mg of talc, and filled in an airtight container to prepare a powder.
< Formulation example Preparation of tablets of pharmaceutical compositions for the treatment of cancer
14.3 mg of 220 (S) -protopaxanol triol was mixed with 97 mg of temozolomide, 100 mg of corn starch, 100 mg of lactose and 2 mg of magnesium stearate, and tableted according to a conventional preparation method.
< Formulation example Preparation of capsules of pharmaceutical compositions for the treatment of cancer
14.3 mg of 20 (S) -protonacoxatriol was mixed with 97 mg of temozolomide, 100 mg of corn starch, 100 mg of lactose and 2 mg of magnesium stearate according to a conventional capsule preparation method and filled in a gelatin capsule to prepare capsules .
Hereinafter, a preparation example of a health functional food containing 20 (S) -protopaxanol triol of the present invention will be described, but the present invention is not intended to be limited thereto but is specifically explained.
< Formulation example 9> Manufacture of Health Functional Foods
(Vitamin A acetate 70mg, Vitamin E 1.0mg, Vitamin B1 0.13mg, Vitamin B2 0.15mg, Vitamin B6 0.5mg, Vitamin B12 0.2mg, Vitamin C 10mg) were added to 14.3mg of 20 (S) , Biotin 10 g, nicotinic acid amide 1.7 mg, folic acid 50 μg, calcium pantothenate 0.5 mg) and an appropriate amount of inorganic mixture (ferrous sulfate 1.75 mg, zinc oxide 0.82 mg, magnesium carbonate 25.3 mg, potassium phosphate monobasic 15 mg, , Potassium citrate (90 mg), calcium carbonate (100 mg) and magnesium chloride (24.8 mg) were mixed to prepare a granule, and a health food was prepared according to a conventional method.
Claims (8)
(I)
(I)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150156097A KR101823343B1 (en) | 2015-11-06 | 2015-11-06 | A composition for enhancing anti-cancer effect of temozolomide comprising 20(s)-protopanaxatriol or salt thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150156097A KR101823343B1 (en) | 2015-11-06 | 2015-11-06 | A composition for enhancing anti-cancer effect of temozolomide comprising 20(s)-protopanaxatriol or salt thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20170053494A KR20170053494A (en) | 2017-05-16 |
| KR101823343B1 true KR101823343B1 (en) | 2018-01-31 |
Family
ID=59035158
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020150156097A KR101823343B1 (en) | 2015-11-06 | 2015-11-06 | A composition for enhancing anti-cancer effect of temozolomide comprising 20(s)-protopanaxatriol or salt thereof |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101823343B1 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030092638A1 (en) * | 2001-09-21 | 2003-05-15 | Dong Huang | Protopanaxadiol and protopanaxatriol and their use as anti-cancer agents |
| WO2008076900A1 (en) | 2006-12-15 | 2008-06-26 | The Uab Research Foundation | Novel ginsenoside compounds, compositions, and methods of use |
| CN104337823A (en) * | 2013-08-01 | 2015-02-11 | 天士力制药集团股份有限公司 | Pharmaceutical composition for restraining tumors |
-
2015
- 2015-11-06 KR KR1020150156097A patent/KR101823343B1/en active IP Right Grant
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030092638A1 (en) * | 2001-09-21 | 2003-05-15 | Dong Huang | Protopanaxadiol and protopanaxatriol and their use as anti-cancer agents |
| WO2008076900A1 (en) | 2006-12-15 | 2008-06-26 | The Uab Research Foundation | Novel ginsenoside compounds, compositions, and methods of use |
| CN104337823A (en) * | 2013-08-01 | 2015-02-11 | 天士力制药集团股份有限公司 | Pharmaceutical composition for restraining tumors |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20170053494A (en) | 2017-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102262306B1 (en) | Composition for relieving premenstrual syndrome and menstrual pain | |
| KR101186898B1 (en) | Antioxidative composition | |
| KR101585074B1 (en) | Composition comprising roasted Cucumis melo L. var makuwa Makino seed extract for treating or preventing cancer | |
| KR101281710B1 (en) | Composition comprising an extact of cirsium japonicum and the compounds isolated thereform for the treatment and preventation of obesity | |
| KR101886350B1 (en) | Composition containing triterpenoid saponin extracted from the root of Camellia sinensis | |
| KR20100129571A (en) | Functional composition for improvement of sex and food having the same | |
| KR102075836B1 (en) | Composition for preventing or treating menopausal syndrome of women comprising Aristotelia chilensis extract, Angelica sinensis extract and Passiflora incarnata extract as an active ingredient | |
| KR20210047594A (en) | Compositions for reinforcing skin barrier and improving atopic dermatitis using hydrangenol or phyllodulcin as an active ingredient | |
| KR101823343B1 (en) | A composition for enhancing anti-cancer effect of temozolomide comprising 20(s)-protopanaxatriol or salt thereof | |
| KR101889418B1 (en) | A composition for enhancing anti-cancer effect of temozolomide comprising 20(s)-protopanaxadiol and salt thereof | |
| KR20180118413A (en) | Composition comprising Cordycepin as an effective ingredient for preventing or treating of Liver cancer and Method for preparing Butanol fraction of Cordyceps militaris | |
| US20090318552A1 (en) | Pharmaceutical composition comprising shikonin derivatives from lithospermum erythrorhizo dor treating or preventing diabetes mellitus and the use thereof | |
| KR101597187B1 (en) | A composition comprising the extract of Melia azedarach showing anti-cancer activity against stomach tumor | |
| KR20210140933A (en) | Composition for preventing or treating sarcopenia comprising blueberry extract | |
| KR101787458B1 (en) | Composition comprising extract of Myristica fragrans Houtt for treating or preventing endometriosis | |
| KR101684574B1 (en) | Pharmaceutical compositions and health functional foods comprising Cibotium barometz J. Smith extracts for preventing or treating anticancer agent-induced of hematopoietic toxicity | |
| KR102448274B1 (en) | Composition for preventing, ameliorating or treating bone disease comprising crude polysaccharide fraction of Psoralea corylifolia extract as effective component | |
| KR20140134774A (en) | Composition comprising complex extract of Astragalus Membranaceus, Schisandra Chinesis and Platycodon grandiflorum for preventing or treating inflammatory disease | |
| KR20180118412A (en) | Composition comprising Cordycepin as an effective ingredient for preventing or treating of Liver cancer and Method for preparing Ethyl acetate fraction of Cordyceps militaris | |
| KR101406126B1 (en) | Composition containing Hedyotis diffusa extract for treating or preventing obesity | |
| KR102595767B1 (en) | Composition for preventing, improving, or treating cachexia containing extract of Buddlejae Flos | |
| KR102599530B1 (en) | A composition for weight control comprising benzopyran | |
| KR102162787B1 (en) | A composition for promoting differentiation of myoblast comprising sabinene | |
| KR101788306B1 (en) | Composition comprising Machilin A for treating or preventing endometriosis | |
| KR101959735B1 (en) | A composition for enhancing anti-cancer effect of cisplatin in colorectal cancer comprising safflower seed extract |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |